Aquestive Therapeutics EBIT

Aquestive Therapeutics (AQST) currently reports a EBIT of $-67M as of June 2026. That compares with $-49M in the prior-year period — down 35.9% year over year. That is below the Healthcare sector average of $23B. Use the charts on this page to explore Aquestive Therapeutics's EBIT history and peer comparisons.

Aquestive Therapeutics's EBIT decreased from $-49M to $-67M — a 35.9% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Aquestive Therapeutics's EBIT of $-67M is lower than the Healthcare sector average of $23B. That is roughly 100.3% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Aquestive Therapeutics reported $-67M in EBIT as of June 2026. That compares with $-49M in the prior-year period — down 35.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-67M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $23B. From there, open related valuation or income-statement pages for Aquestive Therapeutics, and consider following AQST for alerts when major investors trade the stock.